deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT01744223

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)

Sponsor: Bellicum Pharmaceuticals

Conditions Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia Lymphoma Myelodysplastic Syndromes
Interventions BPX-501 dose 1 BPX-501 dose 2 BPX-501 dose 3 BPX-501 dose 4 Rimiducid SCT
Updated 16 times since 2017 Last updated: Jul 10, 2022 Started: Mar 31, 2013 Primary completion: Oct 9, 2019 Completion: Oct 31, 2032
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01744223, this PHASE1/PHASE2 trial focuses on Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia and remains ongoing. Sponsored by Bellicum Pharmaceuticals, it has been updated 16 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Nov 2019 · 8 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Nov 2020 · 11 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Sep 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Dec 2019 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Mar 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Nov 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bellicum Pharmaceuticals
Data source: Bellicum Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations